Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight,but without diabetes: The SCALE Obesity and Prediabetes randomised,double-blind,placebo-controlled 3-year trial 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight,but without diabetes: The SCALE Obesity and Prediabetes randomised,double-blind,placebo-controlled 3-year trial

摘要：
本文献已被 ScienceDirect 等数据库收录！